FIELD: medicine; pharmaceuticals.
SUBSTANCE: described is a pharmaceutical combination of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof and / or solvate together with 4-[(S)-2-azetidine-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide. Combination of said drugs is used in treating cancer.
EFFECT: combination of said drugs provides enhanced anti-tumor efficacy without increasing toxicity.
8 cl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTICOLIC ACTIVITY, WITH MEK INHIBITOR | 2013 |
|
RU2684407C2 |
| 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE FOR USE IN TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC) | 2013 |
|
RU2650679C2 |
| PHARMACEUTICAL PREPARATION | 2020 |
|
RU2822063C2 |
| SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR TREATING VESTIBULAR DISORDERS | 2009 |
|
RU2589846C2 |
| PYRIDINONE PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | 2007 |
|
RU2472782C2 |
| DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | 2014 |
|
RU2662832C2 |
| METHODS FOR TREATMENT OF MALIGNANT TUMOR USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | 2016 |
|
RU2765154C2 |
| 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-HETEROCYCLYL-CARBOXAMIDE DERIVATIVES | 2013 |
|
RU2644761C2 |
| DERIVATIVES OF QUINAZOLINE | 2003 |
|
RU2296757C2 |
| 2,5,7-SUBSTITUTED OXAZOLPYRIMIDINE DERIVATIVES | 2011 |
|
RU2557246C2 |
